Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization
暂无分享,去创建一个
E. Falkowska | J. Reinus | Tatjana Dragic | T. Dragic | Francis Kajumo | F. Kajumo | Emilia Falkowska | Edie Garcia | John Reinus | E. Garcia | Edie Garcia
[1] D. Lavillette,et al. Characterization of host‐range and cell entry properties of the major genotypes and subtypes of hepatitis C virus , 2005, Hepatology.
[2] Charles M. Rice,et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.
[3] T. Dragic,et al. CD81 is an entry coreceptor for hepatitis C virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Houghton,et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Rossmann,et al. Locations of Carbohydrate Sites on Alphavirus Glycoproteins Show that E1 Forms an Icosahedral Scaffold , 2001, Cell.
[6] C. Rice,et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[7] B. Bartosch,et al. Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.
[8] G. Deléage,et al. Conservation of the Conformation and Positive Charges of Hepatitis C Virus E2 Envelope Glycoprotein Hypervariable Region 1 Points to a Role in Cell Attachment , 2001, Journal of Virology.
[9] Anna Tramontano,et al. A model for the hepatitis C virus envelope glycoprotein E2 , 2000, Proteins.
[10] J. Binley,et al. Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits , 2000, Journal of Virology.
[11] S. Levy,et al. In search of hepatitis C virus receptor(s). , 2001, Clinics in liver disease.
[12] M. Clementi,et al. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. , 2004, Virology.
[13] Wei Zhang,et al. Placement of the Structural Proteins in Sindbis Virus , 2002, Journal of Virology.
[14] J. Dubuisson,et al. Characterization of Hepatitis C Virus E2 Glycoprotein Interaction with a Putative Cellular Receptor, CD81 , 1999, Journal of Virology.
[15] J. Dubuisson,et al. Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. , 1999, The Journal of general virology.
[16] T. Liang,et al. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. , 2002, Virology.
[17] M. Major,et al. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. , 2004, Vaccine.
[18] T. Chambers,et al. HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. , 2004, Virology.
[19] Jean Dubuisson,et al. Cyanovirin-N Inhibits Hepatitis C Virus Entry by Binding to Envelope Protein Glycans* , 2006, Journal of Biological Chemistry.
[20] Stephen D Fuller,et al. Low pH induces swiveling of the glycoprotein heterodimers in the Semliki forest virus spike complex , 1995, Cell.
[21] Paul J Maddon,et al. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Clayton,et al. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. , 2001, The Journal of general virology.
[23] N. Kato,et al. Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. , 1995, Biochemical and biophysical research communications.
[24] T. Shikata,et al. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees , 1999, Archives of Virology.
[25] J. Pawlotsky. Hepatitis C virus infection: virus/host interactions , 1998, Journal of viral hepatitis.
[26] T. Dragic,et al. Different Domains of CD81 Mediate Distinct Stages of Hepatitis C Virus Pseudoparticle Entry , 2006, Journal of Virology.
[27] Bette Korber,et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. , 2004, Glycobiology.
[28] W P Havens,et al. Viral hepatitis. , 1970, The Medical clinics of North America.
[29] Man-Fung Yuen,et al. Viral hepatitis B , 2003, The Lancet.
[30] R. Garry,et al. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. , 2003, Virology.
[31] D. Vlahov,et al. Protection against persistence of hepatitis C , 2002, The Lancet.
[32] B. Walker,et al. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.
[33] Charles M. Rice,et al. Flaviviridae :T he Viruses and Their Replication , 2007 .
[34] M. Lai,et al. Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection , 2003, Journal of Virology.
[35] C. Rice,et al. CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection , 2004, Journal of Virology.
[36] R. Cortese,et al. Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor* , 2003, Journal of Biological Chemistry.
[37] M. Houghton,et al. Binding of hepatitis C virus to CD81. , 1998, Science.
[38] E. Schreier,et al. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. , 1995, Virology.
[39] R. Doms,et al. DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] A. Maerz,et al. A Conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr Motif in Hepatitis C Virus Glycoprotein E2 Is a Determinant of CD81 Binding and Viral Entry , 2006, Journal of Virology.
[41] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[42] T. Katayama. Transfusion-associated hepatitis , 1985 .
[43] O. Schwartz,et al. DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2* , 2003, Journal of Biological Chemistry.
[44] S D Fuller,et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. , 2001, Molecular cell.
[45] D. Fry,et al. Hepatitis: an overview of important issues. , 1997, Bulletin of the American College of Surgeons.
[46] R. Cortese,et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.
[47] A. Tramontano,et al. Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2 , 2003, Journal of Virology.
[48] W. Olson,et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[49] S. Emerson,et al. In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[50] R. Purcell,et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[51] J. Navaza,et al. The Fusion Glycoprotein Shell of Semliki Forest Virus An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH , 2001, Cell.
[52] H. Drummer,et al. Hepatitis C Virus Glycoprotein E2 Contains a Membrane-proximal Heptad Repeat Sequence That Is Essential for E1E2 Glycoprotein Heterodimerization and Viral Entry* , 2004, Journal of Biological Chemistry.
[53] R. Doms,et al. Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR , 2003, Journal of Virology.
[54] S. Harrison,et al. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.
[55] E. Keeffe,et al. Quantitative analysis of hepatitis C virus in peripheral blood and liver: replication detected only in liver. , 2001, The Journal of infectious diseases.
[56] J. H. Strauss,et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion , 2002 .
[57] M. Houghton,et al. Perspectives for a vaccine against hepatitis C virus. , 1999, Journal of hepatology.
[58] R. Doms,et al. Quantitative Expression and Virus Transmission Analysis of DC-SIGN on Monocyte-Derived Dendritic Cells , 2002, Journal of Virology.
[59] Birke Bartosch,et al. Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins , 2005, Journal of Virology.
[60] F. Penin,et al. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. , 2000, The Journal of general virology.
[61] P Parham,et al. Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.